Evidence Explorer · MS-N259 · Acupuncture and acupressure · persistent chemotherapy-induced peripheral neuropathy · Appraised November 7, 2026
For cancer survivors with persistent chemotherapy-induced peripheral neuropathy, a four-week ear-seed acupressure program produced an early symptom-response signal, but the primary severity advantage was not sustained consistently and the fully virtual arm had substantial attrition.
Evidence at a glance
- Benefit signal: Both delivery arms had higher odds of a ≥20% improvement in each participant’s worst symptom-location item at week 1; improvement in neuropathy interference was more consistent, especially with in-person placement.
- Certainty: Low. There was no sham or attention control, the ≥20% response threshold differed from the original 30% protocol threshold, and post-intervention completion ranged from 52% to 96% across arms.
- Risk context: No serious intervention-attributable events were reported. Expected issues include local irritation, tenderness, adhesive reaction and displaced seeds.
- Cancer-control relevance: This is supportive-care evidence. It does not test tumor response, recurrence or survival.
What was studied
A U.S. three-arm randomized trial enrolled 227 survivors with pain, numbness or tingling rated at least 4/10 after neurotoxic chemotherapy. Participants received in-person mobile-supported auricular point acupressure (mAPA; n=80), virtual self-placement (vAPA; n=75), or usual care (n=72). Both active arms used Vaccaria seeds for four weeks, with pressing adherence defined as at least nine minutes daily; each received one coaching session. The individualized primary outcome followed the participant’s highest-rated symptom-by-location item.
What the study found
At week 1, the odds of a ≥20% improvement were higher than usual care with mAPA (OR 2.60, 95% CI 1.27–5.33) and vAPA (OR 3.22, 95% CI 1.48–7.01). The mAPA severity advantage persisted at week 2 (OR 2.49, 95% CI 1.19–5.21) but not clearly at weeks 3 or 4; vAPA did not remain significant after week 1. A one-point improvement in interference was more consistent: mAPA exceeded usual care at every assessed week. FACT/GOG neurotoxicity and ECOG performance did not differ significantly.
What this does not establish
The trial cannot separate point-specific effects from attention, coaching, expectancy or natural fluctuation. Differential completion was large—74% mAPA, 52% vAPA and 96% usual care—and the virtual comparison was an active delivery strategy, not a sham. It does not show nerve recovery or prevention of chemotherapy dose changes.
Safety and practical context
Ear seeds avoid needles, but persistent or worsening neuropathy still needs evaluation for falls, weakness, diabetes, vitamin deficiency, spinal disease and medication causes. New asymmetry, motor weakness or bowel/bladder symptoms warrant prompt medical assessment.
Questions for the care team
- Could duloxetine, exercise, balance work or rehabilitation be more appropriate for my symptom pattern?
- Who will place the seeds, how will skin reactions be monitored, and what happens if symptoms worsen?
- Are there neurologic red flags or competing causes that should be investigated first?
Sources and identifiers
Funding and conflicts: The report lists NCI grant R01CA245054 with partial CPRIT support and declares no competing interests.
Source access and dates: Full journal text and PubMed record were appraised. Trial registration: NCT04920097. Sources checked November 7, 2026. Last literature search November 7, 2026.
Educational evidence summary, not individualized medical advice. These approaches should complement—not replace—oncology, rehabilitation, palliative or symptom-directed care.
